Noopept
Noopept (Omberacetam)
Also known as: Omberacetam, GVS-111
A proline-containing dipeptide nootropic approved in Russia, studied for mild cognitive impairment and neuroprotection.
Overview
Noopept is a synthetic proline-containing dipeptide developed in Russia, where it is approved for cognitive and anxiety-related conditions. Research describes increased BDNF and NGF expression and neuroprotective, memory-supporting effects. Evidence outside Russia is limited, and it is not approved by the FDA.
Mechanism of action
Increases BDNF and NGF expression and modulates glutamate signaling, supporting memory and neuroprotection.
Key studies & citations
- Review2002
The original novel nootropic and neuroprotective agent noopept
Russian pharmacology review: noopept is active at doses about 1,000-fold lower than piracetam, with memory, anxiolytic and neuroprotective effects, and is orally active.
Eksperimental'naia i Klinicheskaia Farmakologiia - Animal2008
Noopept stimulates the expression of NGF and BDNF in rat hippocampus
Acute and 28-day noopept increased hippocampal NGF and BDNF mRNA in rats without tolerance.
Bulletin of Experimental Biology and Medicine - Human2008
Clinical and electroencephalographic characteristic of noopept in patients with mild cognitive impairment of posttraumatic and vascular origin
Open Russian clinical study: EEG changes typical of nootropic and anxiolytic action, most evident in cerebrovascular patients; not placebo-controlled.
Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova
Frequently asked questions
Is Noopept a peptide?
It is a dipeptide-derived molecule (a proline-containing dipeptide ester), which is why it is often grouped with peptide nootropics, though it is a small synthetic compound.